Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the best healthcare stocks to buy for 2026. On January 20, RBC Capital reiterated an Outperform rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) but cut the price target to $465 from $500. Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth The new price outlook comes on Alnylam Pharmaceuticals announcing strategic priorities for the year, including achieving revenue of $5.1 billion, exceeding ...

Core Viewpoint - Alnylam Pharmaceuticals, Inc. is considered a strong healthcare stock for 2026, with RBC Capital maintaining an Outperform rating but lowering the price target to $465 from $500 [1]. Group 1: Analyst Views - Alnylam Pharmaceuticals aims for a revenue target of $5.1 billion, surpassing the consensus estimate of $4.7 billion, with a long-term goal of a 25% compound annual growth rate through 2030, leading to projected revenue of $11.2 billion [2]. - Cantor Fitzgerald has a Neutral rating on Alnylam Pharmaceuticals, citing a slowdown in Amvuttra cardiomyopathy sales in November, although sales rebounded in December. The firm anticipates a mid-single-digit decline in Amvuttra's net price by 2026, influencing their cautious outlook [3]. Group 2: Company Overview - Alnylam Pharmaceuticals specializes in developing innovative medicines using RNA interference (RNAi) technology to target and silence disease-causing genes, focusing on treatments for rare and common genetic, metabolic, cardiovascular, and neurological diseases [4].

Company Overview - Arrowhead Pharmaceuticals is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapeutics targeting serious diseases, particularly liver disorders and cardiometabolic conditions [8][9] - The company has a robust clinical pipeline that includes drug candidates such as ARO-AAT, ARO-APOC3, and JNJ-3989, and generates revenue through licensing agreements, research collaborations, and milestone payments from pharmaceutical partners [8][9] - As of the most recent financial data, Arrowhead Pharmaceuticals has 609 employees, a total revenue of $829.45 million, and a net income of -$1.63 million for the trailing twelve months (TTM) [5] Recent Developments - On December 17, 2025, CEO Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals for approximately $5.44 million, which aligns with his historical trading activity [1][2][7] - The sale occurred during a period of significant stock performance, with a total return of 249.37% over the prior year, and the stock closing at $64.80 on the transaction date [2][12] - The timing of the sale suggests it was part of a tax-planning strategy related to performance awards that vested in December [4][11] Market Context - The stock price surged following the FDA approval of Arrowhead's first medicine, plozasiran (marketed as Redemplo), for treating familial chylomicronemia syndrome, reaching a 52-week high of $76.76 on January 6 [12] - The current elevated price-to-sales ratio indicates that while it may be a good time for shareholders to sell, waiting for a price drop before reinvesting could be a more strategic approach [13] Competitive Edge - Arrowhead Pharmaceuticals' competitive advantage lies in its proprietary RNAi delivery technologies, which enable the treatment of previously untreatable diseases [10]

Company Overview - Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a biopharmaceutical company focused on developing medicines that treat intractable diseases through RNA interference (RNAi) therapeutics [1] - The company competes with other biotech firms in the RNAi space, including Alnylam Pharmaceuticals and Ionis Pharmaceuticals [1] Insider Trading Activity - On January 5, 2026, Hamilton James C, the Chief Medical Officer, sold 4,625 shares at $61.24 each, retaining 207,497 shares post-sale [2] - Mauro Ferrari, a Director, sold 7,530 shares at an average price of $70, totaling $527,100, and reduced his ownership by 9.83% [3] - Ferrari previously sold 8,750 shares at $56.39 each, totaling $493,412.50 [3] Stock Performance - Arrowhead's stock opened at $66.39, reflecting a 1.3% decrease, and is currently priced at $63.88, down 5.77% or $3.91 [4] - The stock has fluctuated between $60.62 and $68 during the trading day, with a yearly high of $72.36 and a low of $9.57 [4] - The company's market cap is approximately $8.83 billion [4] Trading Volume and Momentum - The trading volume for ARWR today is 2,692,400 shares [5] - The stock's 50-day moving average is $53.54, indicating recent upward momentum despite recent insider sales [5][6] - Arrowhead remains a significant player in the biopharmaceutical industry, focusing on RNAi therapeutics [6]

Core Viewpoint - Arrowhead Pharmaceuticals, Inc. announced interim results from two Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7, investigational RNA interference therapeutics aimed at treating obesity, showing significant reductions in key health measures [1] Group 1: Clinical Trial Results - The preliminary results indicate meaningful reductions in visceral fat, total fat, and liver measurements, highlighting the potential effectiveness of Arrowhead's new approach to obesity treatment [1]

Core Insights - Alnylam Pharmaceuticals will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:00 am PT [1] - The company plans to unveil its new five-year strategy aimed at guiding its next phase of growth [1] - An update on unaudited fourth quarter and full year 2025 global net product revenues will be shared, along with an outlook for 2026 product sales [1] Company Overview - Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics, focusing on innovative medicines for rare and prevalent diseases with unmet needs [2] - The company has developed commercial RNAi therapeutic products including AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, and collaborates with partners like Novartis and Sanofi for additional products [2] - Alnylam has a robust pipeline of investigational medicines, with multiple candidates in late-stage development [2] Strategic Vision - The company is executing its "5Alnylam Px25" strategy to deliver transformative medicines for both rare and common diseases [2] - Alnylam aims to benefit patients globally through sustainable innovation and exceptional financial performance, establishing a leading profile in the biotech industry [2]

Core Viewpoint - Alnylam Pharmaceuticals is highlighted as a promising biotech stock with significant growth potential, particularly due to its innovative RNA interference (RNAi) therapies and recent product approvals [2][5][13]. Company Overview - Alnylam Pharmaceuticals was co-founded in 2002 by MIT professor Phillip Sharp, who also co-founded Biogen in 1978 [4]. - The company focuses on RNA interference (RNAi) as a novel therapeutic approach, which has gained recognition with a Nobel Prize in 2006 [5]. Financial Performance - An investment of $10,000 in Alnylam at its IPO would be worth approximately $787,000 today, indicating strong historical performance [6]. - The company's market capitalization is currently $61 billion, with a gross margin of 83.90% [9]. Product Pipeline and Growth - Alnylam received FDA approval for its RNAi therapy Onpattro in 2018, targeting a rare genetic disease, and has since launched another therapy, Amvuttra, which is expected to become a blockbuster drug [7][9]. - Sales of Amvuttra increased by 162% year-over-year in Q3 2025, showcasing strong market demand [10]. - The company is evaluating nucresiran in phase 3 clinical studies for additional ATTR indications [10]. Collaborations and Licensing - Alnylam has outlicensed its RNAi therapies, including Leqvio to Novartis and Qfitia to Sanofi, which helps mitigate risk while still generating revenue [9][14]. - The company is collaborating with Regeneron on cemdisiran and with Roche on zilebisiran, expanding its therapeutic reach [11][12]. Future Outlook - Alnylam's forward price-to-earnings ratio is 53.5, reflecting high growth expectations already priced into the stock [13]. - The company’s RNAi platform has the potential to address a wide range of diseases beyond its current focus, suggesting long-term growth opportunities [15]. - While the investment outlook remains uncertain, the company is expected to continue generating significant returns for patient investors [16].

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to complement the Zacks Rank, helping investors identify stocks likely to outperform the market in the short term [2] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum characteristics, with A being the highest score [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - Concentrates on a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - Targets stocks with upward or downward price trends, utilizing recent price changes and earnings estimate revisions to identify buying opportunities [5] VGM Score - Combines Value, Growth, and Momentum Scores to provide a comprehensive assessment of stocks, aiding in the selection of the most attractive investment opportunities [6] Zacks Rank Integration - The Zacks Rank uses earnings estimate revisions to identify stocks with the highest potential returns, with 1 (Strong Buy) stocks historically achieving an average annual return of +23.64% since 1988 [7][8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment success [9] Company Spotlight: Alnylam Pharmaceuticals - Alnylam Pharmaceuticals is a biopharmaceutical company specializing in RNA interference therapeutics, with a pipeline targeting genetic, cardio-metabolic, and hepatic infectious diseases [11] - The company has received multiple FDA approvals for its products, including Onpattro, Givlaari, Oxlumo, and Amvuttra, addressing various medical conditions [11] - Currently, Alnylam has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a strong Momentum Style Score of A, indicating potential for upward movement [12][13]

Core Insights - The FDA has granted fast track designation to Sanofi's SAR446268, a one-time AAV gene therapy for treating non-congenital myotonic dystrophy type 1 (DM1), aimed at expediting its development and review process [1][7] Group 1: Product Development - SAR446268 utilizes a vectorized RNA interference (RNAi) approach to silence DMPK expression, potentially addressing key symptoms of DM1 such as muscle weakness and myotonia [2][3] - The therapy is currently undergoing a first-in-human, phase 1-2 study to assess its safety, tolerability, and efficacy, with the first patient expected to be enrolled in late 2025 [3] Group 2: Disease Overview - Myotonic dystrophy type 1 is a rare genetic disorder affecting approximately 1 in 2,300 people globally, characterized by progressive muscle weakness and various systemic effects [4] - There are currently no approved treatments for DM1, highlighting the unmet medical need that SAR446268 aims to address [4][7] Group 3: Company Profile - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [5]

Core Viewpoint - Silexion Therapeutics Corp. has announced a public offering of 1,500,000 ordinary shares and accompanying warrants at a price of $4.00 per share, aiming to raise approximately $6.0 million to advance its pre-clinical studies and for general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes 1,500,000 ordinary shares, series A warrants, and series B warrants, all priced at $4.00 per share [1]. - Series A warrants will have an exercise price of $4.00, exercisable immediately, and will expire five years from issuance [1]. - Series B warrants will also have an exercise price of $4.00, exercisable immediately, but will expire twelve months from issuance [1]. - The offering is expected to close on or about September 12, 2025, pending customary closing conditions [1]. Group 2: Financial Aspects - The gross proceeds from the offering are expected to be $6.0 million before deducting fees and expenses [2]. - The net proceeds will be utilized to advance pre-clinical studies and for general corporate purposes [2]. Group 3: Company Background - Silexion Therapeutics is focused on developing RNA interference therapies for KRAS-driven cancers, particularly targeting solid tumors with mutated KRAS oncogenes [5]. - The company has conducted a Phase 2a clinical trial for its first-generation product, showing a positive trend compared to chemotherapy alone [5]. - Silexion is committed to advancing therapeutic options in oncology, specifically for locally advanced pancreatic cancer [5].